HALOZYME THERAPEUTICS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.0B | $829.3M | $660.1M | $443.3M |
| Operating income | $469.0M | $551.5M | $337.6M | $267.5M | $275.9M |
| Cost of revenue | $228.8M | $159.4M | $192.4M | $139.3M | $81.4M |
| Cash from operations | $651.6M | $479.1M | $388.6M | $240.1M | $299.4M |
| Capital expenditure | $7.0M | $10.7M | $15.3M | $4.8M | $1.5M |
| Free cash flow | $644.6M | $468.4M | $373.3M | $235.3M | $298.0M |
| Share repurchases | $342.4M | $250.0M | $402.4M | $200.0M | $350.1M |
| Total assets | $2.5B | $2.1B | $1.7B | $1.8B | $1.1B |
| Total liabilities | $2.5B | $1.7B | $1.6B | $1.7B | — |
| Total debt | $2.2B | $1.5B | $1.5B | $1.5B | $895.9M |
Shares outstanding 118.6M · Free float 91.5%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.